Otsuka Pharmaceutical

Doctor diagnoses kidney
Pharma

In a first, Otsuka’s Voyxact stabilizes IgAN kidney loss in ph.3

The first-in-class drug achieved an annualized eGFR slope of a +0.3 mL/min/1.73m² over two years, matching normal levels seen in healthy adults.
Angus Liu Aug 3, 2026 5:00pm
brain

FDA approves Otsuka’s first-in-class ADHD drug Simtriyo

Jul 27, 2026 12:42pm
Several flags representing various European countries blow in the wind The blue starred flag of the European Union is toward

Lilly, Otsuka and more earn nods from Europe's CHMP

Nov 14, 2025 11:52am
Graphic image of a red thumbs down against a blue background

Otsuka, Lundbeck's Rexulti snubbed by FDA in PTSD

Sep 22, 2025 4:42pm
Stop sign

FDA advisors overwhelmingly reject Lundbeck, Otsuka's PTSD drug

Jul 21, 2025 11:34am
newspaper

China biotech deals, Takeda, LaNova—Fierce Pharma Asia

Jul 18, 2025 9:04am